Rituximab and Zanubrutinib for slow-growing B-cell lymphomas
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two targeted drugs (rituximab and zanubrutinib) for people with slow-growing B-cell lymphomas like marginal zone or follicular lymphoma. It may be a good option if you haven't had treatment for your lymphoma before and your disease needs therapy to manage symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have either untreated marginal zone lymphoma or untreated follicular lymphoma (grade 1, 2, or 3a).
- Your lymphoma is active enough to need whole-body treatment (not just radiation) and you have a tumor at least 1.5 cm on a CT scan.
- You are 18 or older and can swallow pills.
- You have not had chemotherapy or immunotherapy for lymphoma before (antibiotics for H. pylori or antivirals for hepatitis C are okay).
- Your lymphoma tests positive for a protein called CD20 on its surface.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two medicines—pirtobrutinib (a targeted pill) and rituximab (an infusion)—for people with marginal zone lymphoma who have not had any prior systemic treatment. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of two targeted drugs (zanubrutinib and rituximab) as a first treatment for marginal zone lymphoma. The goal is to see how well this drug pair works for people who have not received any prior cancer therapy.
This trial tests a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) for people with follicular lymphoma or marginal zone lymphoma that has come back after at least one prior treatment. The goal is to see if this new combination is safe and effective.
This trial tests a combination of two targeted drugs, orelabrutinib and obinutuzumab, for people with a type of slow-growing lymphoma called marginal zone lymphoma who have not had any previous treatment. The goal is to see if this combination can shrink or control the cancer with manageable side effects.
This trial tests a combination of two targeted therapies—oralebrutinib (a pill that blocks a protein in cancer cells) and rituximab (an antibody infusion)—for people with marginal zone lymphoma that has returned or cannot be treated with local therapies. The goal is to see if this combo works well and is safe.
This trial tests a new combination of targeted drugs (zanubrutinib, lenalidomide, and rituximab) against a standard two-drug combination for people with newly diagnosed follicular lymphoma who need treatment right away. It aims to see if the three-drug combo is more effective.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.